Novo to Build Prefilled Insulin Pen Facility in Iran

Novo Nordisk Iran and the Food and Drug Administration of the Islamic Republic of Iran have signed a Memorandum of Understanding committing Novo Nordisk to build a local manufacturing plant for FlexPen prefilled insulin delivery devices in Iran, the company announced in a Sept. 22, 2015 press release.

The project is expected to last five years and represents a Novo Nordisk investment of approximately 70 million Euros (US$78 million). With construction of the GMP facility, Novo Nordisk will create 160 jobs; Novo Nordisk already employs approximately 130 people in Iran.

"We are happy to commit to this manufacturing facility in Iran. It signals our long-term commitment to Iran, a country where close to five million people have diabetes according to the International Diabetes Federation. This investment will ensure availability of our modern insulins and will bring us a step closer to the people who rely on our products," said Ole Moelskov Bech, corporate vice-president of Novo Nordisk business area Near East, in the release.